To include your compound in the COVID-19 Resource Center, submit it here.

Actimmune misses hurdle, but gains gold

Missing the primary endpoint in Phase III trials usually spells doom for investigational drugs, but this might not be the case for Actimmune interferon gamma-1b from InterMune Inc. in idiopathic pulmonary fibrosis (IPF). The product failed to significantly reduce the time to disease progression, the primary endpoint in its Phase III study. However, Actimmune increased patient survival time, an endpoint that could be considered more clinically relevant, given that IPF is a fatal disease.

In the double-blind

Read the full 774 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE